Summary by Futu AI
Johnson & Johnson has announced a supplement to its 2024 Notice of Annual Meeting and Proxy Statement dated March 13, 2024, for the upcoming Annual Meeting of Shareholders scheduled for April 25, 2024. The supplement, which should be read in conjunction with the previously distributed Proxy Statement, provides updated information regarding the meeting. Notably, a shareholder proposal concerning the impact of extended patent exclusivities on patient access, identified as Item 5, has been withdrawn and will not be presented or voted upon at the Annual Meeting. Despite the withdrawal of Item 5, the company has confirmed that the proxy card and voting instruction forms already distributed remain valid. Johnson & Johnson will not be issuing new voting materials, and shareholders who have already submitted their votes do not need to take any further action unless they wish to change their vote. The company has advised those who have not yet voted to complete their proxy card or voting instruction form, disregarding Item 5. All other agenda items are unaffected and will be voted on as instructed.